Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.

Continued here:
Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC